Stemselect Biotech
Pure and Fast Autologous Adipose Stem Cells for Direct Use
Stemselect Biotech
Pure and Fast Autologous Adipose Stem Cells for Direct Use
About Stemselect Biotech
Our Mission
Stemselect was a medical device company developing a rapid, point-of-care solution to isolate pure autologous adipose-derived stem cells for immediate clinical use. Our patented technology was inspired by biological systems and relied on a fully mechanical isolation process, avoiding enzymes or chemical manipulation.
The device was designed to leverage existing, well-characterized medical materials, with the explicit goal of simplifying regulatory pathways—particularly within the complex European medical device landscape.
Stemselect raised close to $1 million in funding, secured three patents, and generated promising preclinical research validating the approach. While the company is no longer active, its work contributed to the broader conversation around safe, compliant, and efficient cell-based therapies.
For inquiries or historical information, please contact us via LinkedIn.